Regulation of Pathogenic CD4 T Cell Responses in Inflammatory Bowel Disease
Immune response in the intestine are tightly regulated to ensure host protective immunity in the absence of immune pathology. A permanent disturbance of this delicate balance can lead to the development of inflammatory bowel disea...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
FLAMINCO
Therapeutic discovery for Inflammatory Bowel Disease
150K€
Cerrado
RTI2018-101291-B-I00
TARGETING NUCLEAR RECEPTOR REV-ERB-ALPHA IN INFLAMMATORY BOW...
145K€
Cerrado
BFU2008-02683
NUEVOS MEDIADORES DE LA RESPUESTA T EFECTORA Y POTENCIAL TER...
121K€
Cerrado
CNS2023-144474
Inmunidad, infección e inmunoterapia
200K€
Cerrado
REINFORCE
Inflammatory Bowel Disease an EU NZ integrated approach for...
536K€
Cerrado
IMMUNOBIOME
Identifying microbiotal triggers of inflammatory bowel disea...
2M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Immune response in the intestine are tightly regulated to ensure host protective immunity in the absence of immune pathology. A permanent disturbance of this delicate balance can lead to the development of inflammatory bowel disease (IBD) comprising Crohn’s disease (CD) and ulcerative colitis (UC). The aetiology of IBD is unknown, but it is thought to involve a complex interplay among genetic, environmental, microbial and immune factors. Dysregulated effector CD4 T cell responses can be causative in IBD irrespective of the initiating events that promote them. There is compelling evidence that pathogenic CD4 T cells accumulate in the inflamed intestine and contribute to the chronicity of disease. Additionally at the onset of IBD, mucosal effector CD4 T cells acquire a pathogenic polyfunctional Th17/Th1 phenotype. However the signals and molecular events that induce and regulate the pathogenic switch in human T cells, remain unknown. Whether this phenotype can be modified in favour of a homeostatic Type 17 or regulatory T cell response also remains to be determined. Revealing the signals and mechanisms by which the differentiation programs of pathogenic CD4 T cells are induced, maintained and modulated, might open new avenues by which pathogenic and chronic CD4 T cell responses can be specifically targeted in IBD.